期刊文献+

索拉非尼联合化疗用于治疗胃癌细胞株的实验研究

Study of Sorafenib combined with chemotherapy on advanced gastric cancer cell line
下载PDF
导出
摘要 目的观察索拉非尼治疗胃癌细胞株的作用机制。方法将胃癌MGC803细胞株扩大培养后,分为4组:对照组,索拉非尼单药组,化疗组,索拉非尼联合化疗同时给药组。各组经处理后观察细胞生长曲线,采用流式细胞仪检测细胞凋亡,MTT检测细胞增殖率,RT-PCR和Western blot法检测EGFR、VEGF的表达。结果索拉非尼联合化疗组细胞增殖率明显下降,细胞明显凋亡。结论索拉非尼联合化疗对胃癌有较好的治疗作用。 Objective To observe Sorafenib for treatment effect advanced garstric cancer cell line.Methods The gastric cancer cell line MGC803 was expanded culture,cell groups: control group,Sorafenib single medicine group,chemotherapy group,Sorafenib combination chemotherapy at the same time giving medicine group.After being treatedal groups was observed for cell growth curve,flow cell meter method measuring cell apoptosis,MTT detection for the cell vitality,RT-PCR and Western blot method measuring the expression of EGFR,VEGF was measued.Results of Sorafenib combined chemotherapy group The ceuvitality declined obviously,and cell apoptosis was significantly.Conclusion Sorafenib combination chemotherapy for gastric cancer has better therapeutic action.
出处 《江西医药》 CAS 2013年第2期95-97,共3页 Jiangxi Medical Journal
基金 江西省卫生厅科技计划(20091007-1)
关键词 索拉非尼 化疗 胃癌细胞株 细胞凋亡 Sorafenib Chemotherapy Gastric cancer celline Apoptosis
  • 相关文献

参考文献10

  • 1Soojh, Choonjj, Sunyret, et al. Growth inhibitory effects of trastuzumab and chemotherapeutic drugs in gastric cancer cell lines[J]. Gancer Letter,2004,214: 215.
  • 2Wilhelm, Carter c, Tangl, et al. BAY 43-9006 exhibits broad spec- trum oral antitumor activity and targets the RAF/MEYdERK path- way and receptor tyrosine kinases involved in tumor progression and angiogenesis[J].Cancer Res,2003,64 (19) :7099.
  • 3Mimori K, Nagahara H, Sudo T, et al. The epidermal growth factor receptor gene sequence is highly conserved in primary gastric can- cers[J]. J Surg Oncol, 2006, 93(1) : 44.
  • 4Dhar A, Mehta S, Banerjee S, et al. Epidermal growth factor recep- tor: is a novel therapeutic target for pancreatic cancer [J].Front B iosci, 2005, 10: 1763.
  • 5Chan JK, Pham H, You X J, et al. Suppression of ovarian cancer cell tumorigenicity and evasion of cisplatin resistance using a trun- cated epidermal growth factor receptor in a ratmodel [J]. Cancer Res, 2005, 65 (8) : 3243.
  • 6Wu X, Deng Y, Wang G, et al. Combining siRNAs at two different sites in the EGFR to suppress its expression, induce apoptos is,and enhance 5-fluorou racilsens it ivity of colon cancer cells[J]. J Surg Res, 2007, 138(1):56.
  • 7Cunningham D, H umblet Y, Siena S, et al. Cetuximab monot hera- py and cetuximab plus irinotecan in irinoteean-refractory nt etas- ta-tic colorectal cancer[J]. N Engl JMed, 2004, 351(4):337.
  • 8Rak J, Yu JL, K lement G, et al. Oncogenes and angiogenesis: s ig- nalingth reed im ensional tumor growth [J]. J In vestig Derm atol SympProc, 2000, 5(1)124.
  • 9Strohmeyer D, Rossing C, Bauerfeind A, et al. Vascular endothelial growth factor and its correlat ionw ith angiogenes is and p53 ex- pression in prostate cancer[J] . Prostate, 2000, 45(3):216.
  • 10Pal S, Claffey KP, Dvorak HF, et al. The yon H ippe-1 L indau geneproduct inhibits vascular penn eability factor/ vascular en- dothelialgrow th factor express ion in renal cell carcinoma by b lock ing proteink inase C pathw ays373276483 [J], J Biol Chem, 1997,272 (44):27509.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部